The prognosis for patients with relapsed versus refractory DLBCL differs significantly, with refractory status generally associated with poorer outcomes. Direct evidence correlates clinical, metabolic, and genetic factors with these prognostic differences, guiding personalized treatment strategies.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: